Do Traders Think GT Biopharma Inc (GTBP) Can Keep Climbing Tuesday?

GT Biopharma Inc (GTBP) stock is higher by 23.78% over the past week and gets a Neutral rating from InvestorsObserver Sentiment Indicator.

GT Biopharma Inc has a Neutral sentiment reading. Find out what this means for you and get the rest of the rankings on GTBP!

See Full GTBP Report

What is Stock Sentiment?

In investing, sentiment generally means whether or not a given security is in favor with investors. It is typically a pretty short-term metric that relies entirely on technical analysis. That means it doesn’t incorporate anything to do with the health or profitability of the underlying company. Sentiment is how investors, or the market, feels about a stock. There are lots of ways to measure sentiment. At the core, sentiment is pretty easy to understand. If a stock is going up, investors must be bullish, while if it is going down, sentiment is bearish. InvestorsObserver’s Sentiment Indicator looks at price trends over the past week and also considers changes in volume. Increasing volume can mean a trend is getting stronger, while decreasing volume can mean a trend is nearing a conclusion. For stocks that have options, our system also considers the balance between calls, which are often bets that the price will go up, and puts, which are frequently bets that the price will fall.

What's Happening With GTBP Stock Today?

GT Biopharma Inc (GTBP) stock is trading at $3.80 as of 3:54 PM on Tuesday, Dec 21, a gain of $0.20, or 5.56% from the previous closing price of $3.60. The stock has traded between $3.46 and $3.80 so far today. Volume today is below average. So far 198,563 shares have traded compared to average volume of 383,254 shares. To see InvestorsObserver's Sentiment Score for GT Biopharma Inc click here.

More About GT Biopharma Inc

GT Biopharma Inc is an immuno-oncology company operating in the United States. It is engaged in discovering, developing and commercializing novel therapeutics from its proprietary product platform in a varied range of disease areas. The company mainly develops drugs focused on the treatment of cancer. Its key drug candidates are OXS-2175, targeting the treatment of triple-negative breast cancer; OXS-4235, targets the treatment of multiple myeloma and associated osteolytic lesions; and OXS-1550, targets cancer cells expressing the CD19 receptor and CD22 receptor. Its TriKE and TetraKE platforms offer immuno-oncology products that can treat a range of hematologic malignancies, sarcoma, and solid tumors. Click Here to get the full Stock Report for GT Biopharma Inc stock.